Edmond DE Rothschild Holding S.A. Invests $254,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Edmond DE Rothschild Holding S.A. purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,500 shares of the company's stock, valued at approximately $254,000.

Several other institutional investors also recently modified their holdings of HIMS. Crewe Advisors LLC purchased a new stake in Hims & Hers Health during the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in Hims & Hers Health in the 4th quarter worth approximately $38,000. Institutional investors own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HIMS shares. Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Piper Sandler upped their target price on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Finally, Needham & Company LLC raised their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a report on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $37.31.

Remove Ads

Hims & Hers Health Price Performance

NYSE:HIMS traded up $1.72 during trading hours on Monday, reaching $27.71. The company's stock had a trading volume of 26,460,112 shares, compared to its average volume of 14,777,841. The company has a market cap of $6.16 billion, a price-to-earnings ratio of 62.97 and a beta of 1.65. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The business's 50-day moving average is $39.76 and its 200-day moving average is $30.11.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $24.44, for a total value of $283,039.64. Following the sale, the chief financial officer now directly owns 118,077 shares of the company's stock, valued at approximately $2,885,801.88. This trade represents a 8.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 2,203 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total value of $63,402.34. Following the transaction, the insider now directly owns 8,007 shares of the company's stock, valued at $230,441.46. This represents a 21.58 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 809,806 shares of company stock valued at $30,923,658 over the last 90 days. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.